Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)
The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
Drug: MK0653, ezetimibe
Drug: Comparator: ezetimibe, placebo
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.|
- Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment.
- Safety and tolerability.
|Study Start Date:||March 2003|
|Study Completion Date:||August 2004|
|Primary Completion Date:||July 2004 (Final data collection date for primary outcome measure)|
The duration of treatment is 10 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00092625
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|